Additionally, it has previously been described that HER2- ER+/− breast cancer patients had an increased frequency of Th2/ Th17 cells, based on the surface marker expression of CXCR3, CCR4, and CCR667. The gene discussed is CXCR3; the disease is breast carcinoma.